biostudies-literatureUnknown16(6)Zhu YRNF114, a member of the E3 ubiquitin ligase family, was first identified as a zinc-binding protein that exhibits frequent genomic amplification across various cancers. Previous studies have shown that inhibition of RNF114 E3 ligase activity by Nimbolide treatment can result in trapping of PARP1 and synthetic lethality in BRCA-mutated cancers, suggesting its E3 ligase role in tumor progress. However, it's important to reveal novel functions and interacting molecules of RNF114. Here, we first described that RNF114 promotes tumor proliferation and autophagy by interacting with EWSR1 and regulating VEGFR2 expression in HER2-positive breast cancer (BC). Our results also showed that RNF114 is significantly overexpressed in BC and is associated with TNM stage and poor prognosis in BC patients. AnJournal of Cancer1888-1904https://www.ebi.ac.uk/biostudies/studies/S-EPMC11905403biostudies-literatureRNF114 Interacts with EWSR1 to Regulate VEGFR2 in HER2-positive Breast Cancer.PMC11905403Zhu YZhang JLu YJiang WLin XMa YTao DYin LSong YfalseRNF114 Interacts with EWSR1 to Regulate VEGFR2 in HER2-positive Breast Cancer.RNF114, a member of the E3 ubiquitin ligase family, was first identified as a zinc-binding protein that exhibits frequent genomic amplification across various cancers. Previous studies have shown that inhibition of RNF114 E3 ligase activity by Nimbolide treatment can result in trapping of PARP1 and synthetic lethality in BRCA-mutated cancers, suggesting its E3 ligase role in tumor progress. However, it's important to reveal novel functions and interacting molecules of RNF114. Here, we first described that RNF114 promotes tumor proliferation and autophagy by interacting with EWSR1 and regulating VEGFR2 expression in HER2-positive breast cancer (BC). Our results also showed that RNF114 is significantly overexpressed in BC and is associated with TNM stage and poor prognosis in BC patients. An2025-01-01T00:00:00Z20252025-04-04T14:48:56.352Z2025-04-04T14:48:56.352ZS-EPMC119054034009269110.7150/jca.106001